278P - The Impact of Progesterone Receptor on Node-Negative Breast Cancer Survival

Abstract

ABSTRACT Background The aim of this study was to evaluate tumor characteristics and survival rates of node-negative breast cancer patients according to progesterone receptor (PR) status. Methods Of 2,218 breast cancer cases diagnosed between 1995 and 2011 in Hacettepe University, Institute of Oncology; 864 node-negative patients with known hormone receptor status were analyzed for age, tumor size, grade, lymphovascular invasion and HER-2/neu status. Estrogen receptor (ER), PR and HER-2 status were determined using immunohistochemistry. Patients were classified into four groups; ER + /PR + , ER + /PR-, ER-/PR+ and ER-/PR-. Pearson Chi-Square test and Kaplan-Meier with log-rank test were performed for statistical analysis. Results 575 (66.6%) patients had ER + PR + , 64 (7.4%) had ER + PR-, 43 (5.0%) had ER-PR+ and 182 (21.1%) had ER-PR- tumor. The median age of patients were 48 years (20-83) and were similar in all groups (p = 0.18). Majority of patients with PR- tumors were postmenopausal at the time of diagnosis (p = 0.021). The follow-up period was 39.5 (1-273) months. Conclusions Patients in PR- groups are more likely to have large-size and HER-2 positive breast cancer. ER- groups are associated with high grade disease. Patients with PR+ breast cancer have significantly longer overall survival, compared to patients with ER+ tumors. Our data suggest that PR status is an important prognostic factor for node-negative breast cancer survival. Disclosure All authors have declared no conflicts of interest.